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Myelodysplastic syndromes (MDS) are a heterogeneous group of disorders characterized by 
ineffective hematopoiesis, cytopenia, and risk of evolution into Acute Myeloid Leukemia 
(AML). It was shown that anemia strongly impacts on the quality of life of patients with MDS. 
Red blood cell (RBC) transfusion represents the main supportive care for patients with 
chronic anemia including MDS, aplastic anemia (AA), and myelofibrosis (PMF). One of the 
most dangerous side effects of RBC transfusions is represented by iron overload (IOL). The 
deleterious impact of IOL has been largely demonstrated in patients affected by B-thalassemia
but more recent evidences, mainly coming from retrospective studies, show that, even in MDS,
IOL might have a negative impact on life expectancy and probably on transfusion requirement
[1]. Adequate iron chelation therapy for at least six months improves survival in transfusion-
dependent patients with lower risk myelodysplastic syndromes.
Many iron chelators have been developed over the years to reduce the iron burden mainly in 
patients with -thalassemia. More recently, the development of the oral iron chelator β-thalassemia. More recently, the development of the oral iron chelator 
deferasirox (DFX) focused the attention on the IOL damage even in patients with MDS. 
Derefasirox has been shown in prospective studies to be effective in reducing iron overload in
patients with MDS with an acceptable toxic profile and good tolerability [2, 3].
Among the benefits of iron chelation, the hematological improvement and transfusion 
independence sporadically reported in patients treated with iron chelation is of particular 
interest [4, 5].
Prospective data obtained in a significant cohort of patients affected by MDS enrolled in the 
EPIC study and treated with deferasirox reported a percentage of 22.6% of erythroid 
responses [2]. However, there are limited data available outside of clinical trials in unselected 
patient.
Before the approval of deferasirox, deferoxamine (DFO) was the only iron chelator approved 
for the treatment of transfusion-dependent iron overload. At that time, very few patients with 
MDS received DFO, a cumbersome drug especially for elderly patients. With the introduction 
of deferasirox in the clinical practice, a significant number of MDS patients started iron 
chelation according to national and international guidelines.
The present study is a “real-life” picture of erythroid responses in a large cohort of chronic 
anemia with iron overload consecutively treated with iron chalation therapy (ICT), either 
with DFX or with DFO, in six Italian hematological centers from 1993 to 2011. Starting from a 
cohort of 156 patients with chronic anemia and IOL treated with iron chelation, 98 patients 
were finally included in the study. Forty-six patients were excluded because they received ICT
for less than 3 months with a drop out rate of 29%, 10 were excluded because they received 
additional therapies able to modify the erythroid response and two were excluded due to the 
absence of the basal serum ferritin level. Among the 98 patients included, 65 were male and 
33 female. The median age was 72 years. The final cohort included: 69 MDS, four chronic 
myelomonocytic leukemia (CMML), 15 myelofibrosis (PMF), two AML, and eight aplastic 
anemia (AA). Among MDS, two were 5q- syndrome, 25 refractory anemia (RA), 20 refractory 
anemia with sideroblasts (RARS), four unclassified MDS (MDS-U), nine refractory cytopenia 
with multilineage dysplasia (RCMD), five refractory anemia with excess of blasts (RAEB I), 
and four refractory anemia with excess of blasts (RAEB II). Fifty-six were low or intermediate 
I IPSS risk and 13 were intermediate II or high risk.
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Thirty patients received deferoxamine and 68 deferasirox. The median dose of deferoxamine 
was 30 mg/kg and the median dose of deferasirox was 15 mg/kg. The median serum ferritin 
level at the time of ICT was 2530 ng/ml and it was not significantly different between the two 
cohorts (p = .8). The median transfusion requirement was 3.2 RBC units/month. Patients, at 
the time of ICT, had transfused a median of 30 RBC units. Hematological response (HR) was 
evaluated according to IWG criteria [6] as follows: achieving a RBC transfusion independency 
(complete HR) or hematological Improvement erythroid (HI-e) for patients showing a 
hemoglobin (Hb) increase of 1.5 g/dL or a reduction of 4 RBC transfusions/8 weeks.
Forty-one patients out of 98 (41.8%) evaluable patients achieved a hematologic response 
(Figure 1, panels A and B). In details, 18 (18.3%) became completely RBC transfusion 
independent, six were under DFO treatment, and 12 under DFX. The median time to response,
evaluated only in patients achieving complete transfusion independence, was 15 months for 
DFO and 3 months for DFX. Sixteen patients (16.3%) obtained HI-e defined as a reduction of 4 
U/8 weeks (five in DFO and 11 in DFX cohorts) after a median of 6 months for both DFO and 
DFX. HI-e defined as an increased of 1.5 g/dL was observed in seven patients (7.1%) after a 
median of 6 months for DFO and three for DFX. Interestingly, the hematologic improvement is
not strictly related to an effective reduction of serum ferritin (p = .4).
Curiously, the four AA patients who achieved independency from RBC transfusions 
significantly increased the number of platelets and become platelet transfusion independent 
(median value of platelets: 17,000/mm3 before ICT and 35,000/mm3 and 55,000/mm3 after 
6 and 12 months of ICT, respectively).
Finally, for 68 patients, a long-term follow up was available (32 responder patients and 36 
non-responder patients). The follow-up of the remaining 30 patients is not available because 
six patients underwent hematopoietic stem cell transplantation, 12 patients died, 12 were lost
at follow-up because they were followed in home day care. The median follow up for 
responder patients was 18 months from the achievement of the hematological response and 
21 months from iron chelation for non-responder patients. After 12 months, 40.6% of the 
patients (13 out of 32) maintained the hematological improvement (Figure 1, panels C and D).
The duration of response is longer for patients treated with DFO compared with DFX. The 
molecular basis of erythroid response is still too obscure to allow an explanation of this 
observation. What is becoming more and more evident is that the two drugs acts with 
different mechanisms. One example is represented by our previous study which 
demonstrated that DFX but not DFO acts as a potent NF-kB inhibitor [7]. The present study 
suggests that the hematological improvement observed during DFX treatment is probably not 
strictly related to an efficient iron removal since it occurs early during ICT when the serum 
ferritin is often still high. By contrast, the effect of DFO seems to parallel the iron chelation. 
This can be only speculated by the data provided and not definitively proved. To address this 
point, further studies are required.
Our data show a high rate of complete responses, mainly in AA and RARS but also in high-risk 
MDS/AML representing 11% of those achieving complete transfusion independency. Notably 
50% of AA achieved RBC and platelet transfusion independency. Despite the limitation due to 
the retrospective collection of data, we suggest the ICT could result in hematologic 
improvement in a wide population including patients who are, at present, outside the 
published ICT guidelines. This study warrants further investigation on the mechanism of 
action of ICT in inducing hematological improvement.
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Figures
Figure 1.
Panel A: cumulative incidence of erythroid response in the entire cohort of patients and 
(panel B) in the same cohort divided accordingly to the treatment the patients received. DFX: 
deferasirox; DFO: deferoxamine. Panel C: duration of erythroid response during ICT in the 
entire cohort of patients and (panel D) in the same cohorts of patients according to the 
treatment the patients received. DFX: deferasirox; DFO: deferoxamine.
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